Used in pharmaceutical research as a key scaffold in the development of kinase inhibitors, particularly targeting enzymes involved in inflammatory and oncogenic pathways. Its fused heterocyclic structure enhances binding affinity to ATP pockets in protein kinases, making it valuable in designing selective inhibitors. The trifluoromethyl group improves metabolic stability and membrane permeability, which enhances oral bioavailability in preclinical drug candidates. Additionally, the furan and hydroxyl moieties allow for further chemical modifications, enabling structure-activity relationship optimization. It has shown promising activity in early-stage studies for cancer and autoimmune diseases.